VYNE Therapeutics has declared a special cash dividend of $0.38 per share in connection with its pending merger with Yarrow Bioscience, Inc. The aggregate dividend is estimated at $16.5 million, based on approximately 42.99 million outstanding shares and equivalents as of July 9, 2026. Stockholders and warrant holders of record as of July 22, 2026 will be eligible for the distribution, with funds remitted to the transfer agent on July 23 and disbursements expected a few days later. The final per-share amount may be subject to minor adjustments based on net cash before closing. Payment is strictly conditioned on the merger closing, which is projected for on or about July 24, 2026, pending stockholder approval at a special meeting on July 16, 2026.
Yarrow Bioscience IncVYNE declares a special dividend contingent on merger closing, providing a direct cash return to shareholders.
Yarrow is the merger partner; the dividend is paid by VYNE, not Yarrow, but the merger is a key event for Yarrow.